AGO2 and breast cancer: As AGO2 has been shown to be able to bind chromatin in human cancer cells [49], ChIP-Seq was performed with anti-AGO2 antibodies in Ct-ERβ and, as control, in wild-type MCF-7 cells to investigate the possibility that this protein also binds to BC cell chromatin, alone and in combination with ERβ, where a complex between the two factors could exert specific actions.